Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katelyn Brown

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Managed Care & Specialty Pharmacy|June 26, 2020
Treatment Patterns and Characteristics of Individuals Initiating High-Dose Insulin for Type 2 Diabetes MellitusJieling Chen, Radhika Nair, Mir Siadaty, et al.
Lancet (London, England)|August 9, 2021
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trialBernhard Ludvik, Francesco Giorgino, Esteban Jódar, et al.
The Journal of Clinical Endocrinology and Metabolism|January 22, 2024
Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)Juan P Frias, Christophe De Block, Katelyn Brown, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 15, 2018
Risk Factors for Transfusions Following Total Joint Arthroplasty in Patients With Rheumatoid ArthritisElizabeth Salt, Amanda T Wiggins, Mary Kay Rayens, et al.
The New England Journal of Medicine|June 25, 2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesJuan P Frías, Melanie J Davies, Julio Rosenstock, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2023
Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 StudiesGarrett R Mullins, Michael E Hodsdon, Ying Grace Li, et al.
Cardiovascular Diabetology|February 10, 2024
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial ProgramStephen J Nicholls, Santiago Tofé, Carel W le Roux, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 1, 2023
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial ProgrammeKristina S Boye, Vivian Thuyanh Thieu, Hélène Sapin, et al.
British Journal of Sports Medicine|April 14, 2021
Effects of wearing a cloth face mask on performance, physiological and perceptual responses during a graded treadmill running exercise testSimon Driver, Megan Reynolds, Katelyn Brown, et al.
The Lancet Regional Health. Western Pacific|June 22, 2026
High-dose, short-course primaquine after point-of-care G6PD testing for the radical cure of <i>Plasmodium vivax</i> malaria: a safety study in Papua New Guinea and IndonesiaLiony Fransisca, Maria Ome-Kaius, Moses Laman, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Managed Care & Specialty Pharmacy|June 26, 2020
Treatment Patterns and Characteristics of Individuals Initiating High-Dose Insulin for Type 2 Diabetes MellitusJieling Chen, Radhika Nair, Mir Siadaty, et al.
Lancet (London, England)|August 9, 2021
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trialBernhard Ludvik, Francesco Giorgino, Esteban Jódar, et al.
The Journal of Clinical Endocrinology and Metabolism|January 22, 2024
Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)Juan P Frias, Christophe De Block, Katelyn Brown, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 15, 2018
Risk Factors for Transfusions Following Total Joint Arthroplasty in Patients With Rheumatoid ArthritisElizabeth Salt, Amanda T Wiggins, Mary Kay Rayens, et al.
The New England Journal of Medicine|June 25, 2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesJuan P Frías, Melanie J Davies, Julio Rosenstock, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2023
Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 StudiesGarrett R Mullins, Michael E Hodsdon, Ying Grace Li, et al.
Cardiovascular Diabetology|February 10, 2024
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial ProgramStephen J Nicholls, Santiago Tofé, Carel W le Roux, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 1, 2023
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial ProgrammeKristina S Boye, Vivian Thuyanh Thieu, Hélène Sapin, et al.
British Journal of Sports Medicine|April 14, 2021
Effects of wearing a cloth face mask on performance, physiological and perceptual responses during a graded treadmill running exercise testSimon Driver, Megan Reynolds, Katelyn Brown, et al.
The Lancet Regional Health. Western Pacific|June 22, 2026
High-dose, short-course primaquine after point-of-care G6PD testing for the radical cure of <i>Plasmodium vivax</i> malaria: a safety study in Papua New Guinea and IndonesiaLiony Fransisca, Maria Ome-Kaius, Moses Laman, et al.
Pageof 2